BRIEF COMMUNICATION: Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports

BRIEF COMMUNICATION: Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports

Rituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20 super(+) B-cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Internal medicine journal 2006-04, Vol.36 (4), p.260-262
Hauptverfasser: Lim, S W, Gillis, D, Smith, W, Hissaria, P, Greville, H, Peh, CA
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Rituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20 super(+) B-cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab and review current reports on the use of rituximab in SLE.
ISSN:1444-0903
1445-5994
DOI:10.1111/j.1445-5994.2006.01055.x